Retractable Technologies Inc (NYSE: RVP)

Retractable Technologies, Inc. manufactures and markets safety medical products, predominantly syringes and needles, for the healthcare industry. The company’s core offerings include the VanishPoint® line of retractable syringes, the Patient Safe® series, and the EasyPoint® retractable needle platform. These products incorporate safety mechanisms designed to protect healthcare workers from needlestick injuries and to reduce cross contamination. Retractable Technologies, Inc. operates manufacturing facilities in Little Elm, Texas and utilizes contract manufacturers in China to support production. The firm also invests in expanding domestic capacity through government agreements to lessen reliance on imported components.

Revenue is generated from the sale of injection devices sold under the VanishPoint®, Patient Safe®, and EasyPoint® brands. In recent years, VanishPoint® 1mL syringes have represented the largest share of sales, accounting for 65.1% of revenue in 2025, 68.5% in 2024 and 78.3% in 2023. EasyPoint® products contributed 31.2% of sales in 2025, 27.1% in 2024 and 16.6% in 2023. The company distributes its products through general line and specialty distributors within the United States and through international distributors abroad. Purchasing decisions are frequently made by group purchasing organizations and institutional buying groups that supply hospitals, clinics and alternate care sites.

Retractable Technologies, Inc. competes in the safety syringe and needle market against larger established firms such as Becton, Dickinson and Company and its spun off entity Embecta Corp. The company’s competitive advantages stem from its proprietary retractable technology that allows needle retraction while the needle remains in the patient. VanishPoint® 1mL syringes meet low dead space criteria set by pharmaceutical manufacturers, which reduces medication waste and can permit additional doses from a vial. EasyPoint® needles provide automated retraction that can be activated with fluid in the syringe, enabling use in blood collection and aspiration procedures. Retractable Technologies, Inc. emphasizes lower lifecycle costs by factoring in reduced needlestick injury treatment and disposal expenses, allowing its price to be competitive or lower than rivals.

The company sells its products to healthcare providers including hospitals, outpatient clinics, alternate care sites and long term care facilities. A significant portion of sales is domestic, with the majority of purchases made through group purchasing organizations that negotiate contracts on behalf of their members. These organizations often enter into agreements with large distributors, which can limit market entry for smaller competitors. Retractable Technologies, Inc. also supplies the United States government through agreements such as the Technology Investment Agreement with the Department of Defense and BARDA, supporting domestic manufacturing capacity. Internationally, the company relies on distributors to reach customers in foreign markets, though international sales represent a smaller share of total revenue.